Intra-Cellular Q1 2023 Earnings Report
Key Takeaways
Intra-Cellular Therapies reported Q1 2023 financial results, highlighted by a significant increase in total revenues to $95.3 million compared to $35.0 million in the same period of 2022. The growth was primarily driven by net product sales of CAPLYTA, which reached $94.7 million, representing a 173% increase year-over-year. The company also announced positive results from a clinical study evaluating lumateperone in patients with mixed features in major depressive disorder and bipolar depression.
Total revenues for Q1 2023 reached $95.3 million, a significant increase from $35.0 million in Q1 2022.
CAPLYTA net product sales were $94.7 million in Q1 2023, up 173% compared to $34.8 million in the same period last year.
CAPLYTA total prescriptions increased by 159% compared to Q1 2022 and 16% sequentially versus Q4 2022.
The company reiterated its CAPLYTA net product sales guidance for 2023, projecting $430 to $455 million.
Intra-Cellular
Intra-Cellular
Forward Guidance
Intra-Cellular Therapies reiterated its financial guidance for FY 2023, including CAPLYTA net product sales of $430 to $455 million.